Mansilla-Vivar R, Segovia-Vergara E. Endoscopic ultrasonography as a comprehensive tool in the evaluation of pancreatic lesions. World J Gastrointest Endosc 2025; 17(9): 111000 [DOI: 10.4253/wjge.v17.i9.111000]
Corresponding Author of This Article
Rodrigo Mansilla-Vivar, FASGE, MD, Assistant Professor, Associate Professor, Endoscopy Unit, Hospital Puerto Montt, Los Aromos 65, Puerto Montt 5480000, Los Lagos, Chile. rmansillavivar@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Endosc. Sep 16, 2025; 17(9): 111000 Published online Sep 16, 2025. doi: 10.4253/wjge.v17.i9.111000
Endoscopic ultrasonography as a comprehensive tool in the evaluation of pancreatic lesions
Rodrigo Mansilla-Vivar, Eduardo Segovia-Vergara
Rodrigo Mansilla-Vivar, Endoscopy Unit, Hospital Puerto Montt, Puerto Montt 5480000, Los Lagos, Chile
Rodrigo Mansilla-Vivar, Eduardo Segovia-Vergara, Facultad de Medicina Y Ciencia, Universidad San Sebastián, Puerto Montt 5480000, Los Lagos, Chile
Co-first authors: Rodrigo Mansilla-Vivar and Eduardo Segovia-Vergara.
Author contributions: Mansilla-Vivar R and Segovia-Vergara E conceived the review topic, conducted the literature search, complied the references and drafted the initial version of the manuscript, they contributed equally to this article, they are the co-first authors of this manuscript; and all authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rodrigo Mansilla-Vivar, FASGE, MD, Assistant Professor, Associate Professor, Endoscopy Unit, Hospital Puerto Montt, Los Aromos 65, Puerto Montt 5480000, Los Lagos, Chile. rmansillavivar@gmail.com
Received: June 20, 2025 Revised: June 30, 2025 Accepted: August 8, 2025 Published online: September 16, 2025 Processing time: 84 Days and 9.2 Hours
Abstract
This article expands upon of endoscopic ultrasound’s (EUS) role in the evaluation of pancreatic lesions, building on findings presented by Ayesha et al and Tasneem et al regarding neuroendocrine tumors. We emphasize the diagnostic and therapeutic utility of EUS not only in solid pancreatic tumors but also in the increasingly prevalent cystic lesions, highlighting its particular relevance in resource-limited settings. By integrating high-resolution imaging, tissue acquisition, biomarker analysis, and minimally invasive interventions into a single platform, EUS addresses key diagnostic and therapeutic challenges, reducing the need for multiple costly procedures and enabling effective management even when access to advanced technologies is limited.
Core Tip: Endoscopic ultrasound (EUS) is a minimally invasive, high-resolution modality with growing relevance in the diagnosis and management of pancreatic diseases. In solid tumors like neuroendocrine tumors, EUS combined with fine-needle biopsy enables accurate histological characterization and prognostic stratification. In cystic lesions, EUS-guided fluid analysis using accessible biomarkers such as carcinoembryonic antigen and glucose allows for clinically meaningful subclassification. Additionally, EUS provides therapeutic options including drainage of fluid collections, celiac plexus neurolysis, and tumor ablation. This integrated versatility makes EUS particularly valuable in resource-constrained healthcare settings.
